Array Technologies Inc (ARRY)

[island man]

Maybe time to pick some up

[4starman]

Looks like it just touched the oversold line.

[DCALongRun]

Don't know looks like a major selloff. We broke a lot of support levels today. Technicals don't look good from a trading viewpoint. Trendline is look bad lower highs and lower lows. Rsi has not gone low enough for entry point for a swing trade.

[4starman]

What's causing the big drop today?

[XenaLives]

IMO - the bottom is in.

[DCALongRun]

We don't know. Those could be the reasons or maybe the options are part of his compensation and he wants diversification. You would think with things coming down the pipeline that he would hold on to his shares. Something to remember is that the pps was $2.5 last Feb 2016. It recovered to $4.00 by August and then shot up like a rocket.

I sold at $11.77 and $11.40 to lock in my profits. With possible massive correction in the major indexes and impact on biotechs in general I will wait for a bottom before getting back in.

[tiv111]

If I'm reading the chart correctly, he sold 30,000 shares at a huge profit (makes sense) but then he sold another 5,000 shares at a loss? Why would he do that? Seems like he must have needed the the cash for something. Maybe he is buying a house or something.

[DCALongRun]

Array Biopharma Inc (ARRY) Director Sells $231,750.00 in Stock

https://www.sec.gov/Archives/edgar/data/1100412/000156218017001360/xslF345X03/primarydocument.xml

[DCALongRun]

There are groups of daytraders who short and long this stock every day. Use the dips to accumulate if you think pps is a bargain.

I have trades this a few times and made good profits. I'm am waiting for a bottom before I get back in.

[XenaLives]

Ipatasertib is P2, partnered with Genentech. Apparently it was chosen because of Zaida's unusual genetic mutation. Given the pipeline I see no reason why this news should trash the share price, but the Market can make a mountain out of a molehill

http://www.arraybiopharma.com/product-pipeline

[XenaLives]

Ipatasertib / GDC-0068
Target: AKT | Indication: Solid Tumors

Introduction / Brief Description
Ipatasertib is an AKT inhibitor invented by Array under a collaboration agreement with Genentech. Array has received certain clinical milestones and is entitled to additional potential clinical and commercial milestones and royalties on product sales under the agreement.

AKT activity is frequently elevated in cancer via multiple mechanisms, including loss of function of the PTEN tumor suppressor gene or mutations/amplifications of the PIK3CA or AKT genes. AKT pathway activation is associated with poor prognosis and may lead to resistance to chemotherapy. Ipatasertib is advancing in clinical development including three Phase 2 trials in patients with breast cancer, gastric cancer and prostate cancer.

- See more at: http://www.arraybiopharma.com/product-pipeline/other-compounds/ipatasertib-gdc-0068/#sthash.2neTfebj.dpuf

[XenaLives]

Apparently Zaida's cancer was extremely rare and unusually complex.

Archer found a unique gene fusion, which happens when one gene breaks and joins with another. This fusion contained the gene AKT1, known among oncologists as the wellspring of tumors. But this particular presentation was unique.

"Nobody's ever seen an AKT1 fusion before," Amsbaugh said. "No one's ever looked for it because it was not reported in scientific literature."

For science, it was a solid breakthrough. For Zaida, it was a miracle.

Her cancer had been notoriously difficult, not only to treat but even to name.

Since she first presented with a tumor at the age of three, various physicians have argued back and forth over whether it was a pediatric presentation of mesothelioma or of ovarian cancer.

Both are rare in people younger than 40, and even more so in pre-pubescent patients.

"The general consensus is mesothelioma," said Mattson. "I generally will call it a more generic term, peritoneal carcinomatosis" — a rare type of cancer that occurs in the thin layer of tissue that covers abdominal organs and surround the abdominal cavity.

After Archer's sequencing, it no longer mattered what to call the disease; the gene had been isolated. Like picking out the single off-tune violinist in the New York Philharmonic Orchestra, now the problem could, hopefully, be corrected.

'Out of hope'

Archer's team reached out to another Boulder company, Array BioPharma.

Array focuses on targeted treatments for cancer. It had a drug, previously developed, that would work at the AKT1 gene: ipatasertib. It was being tested in a handful of clinical trials; none of which were open to children.

By this point, Zaida had deteriorated further.

"You could actually see the (tumors) in the lungs protruding out on her right side," Ellefson said. "She couldn't walk for very long; she had to be pushed in stroller."

Mom Mattson started to put the pressure on teams at Archer and Array, willing them to find a solution, and fast.

"I was trying to rush things along. Surgery wasn't an option. We were running out of drugs to try. We needed this in a hurry."

Array's head of drug development scoured her network, connecting with doctors in Denver and New York. The Food and Drug Administration was brought in, mercifully granting what's called a compassionate use approval for the drug.

Now, Zaida was essentially in a one-person clinical trial for an unproven and unapproved drug. She flew with her mother to Memorial Sloan-Kettering Cancer Center in New York to begin the treatment.

"This was a long shot," said Ellefson. "But we were out of hope."

http://www.dailycamera.com/lafayette-news/ci_30604843/boulder-biotech-breakthrough-eases-lafayette-girls-long-cancer

[XenaLives]

Newspaper story on Zaida's compassionate use...

http://www.dailycamera.com/lafayette-news/ci_30604843/boulder-biotech-breakthrough-eases-lafayette-girls-long-cancer

[XenaLives]

Zaida died - I don't know what implications that has for the drug overall though.

http://www.timescall.com/top-stories/ci_30861962/despite-hope-bioscience-firms-breakthrough-cancer-treatment-lafayette

[yankees7]

judging from your reply BR has jumped on some negative news - he is the perfect definition of a short - they do not miss a beat to instill the worst - the ignore filter is really the way to go here

[vidpok45]

Please tell our best bud that I am ok, lol. Still alive and kicking. Is AUPH really next? I guess if ARRY goes down, alphabetically AUPH is the next to go down. Crap, what to do? Thanks BR for having our back!

[trading_cyclist]

I so miss you BR!!! But where's little 2Da? Is he still holed up in the orphanage? Oops, gotta reactivate the blocking filter. Ba Bye!!

[biotech_researcher]

TC, I'm glad to see that you have made a speedy recovery and are back with your sarcastic dialog!

[trading_cyclist]

Oh there you are again, cutie!! Had the spam filter on and didn't see you.

And good God, IS AUPH really next????


Nooooooooooooooo!! Say it's not true, please say it's not true, PLEASE!!!!

[biotech_researcher]

ARRY was on of Vid's holdings. Hope he is OK.. AUPH next?

[yankees7]

Array BioPharma Provides NEMO Update
- NRAS-mutant melanoma NDA withdrawn based on thorough discussions with FDA and following late cycle review meeting -
- Ongoing binimetinib clinical studies will continue; withdrawal will not impact planned COLUMBUS NDA submission of binimetinib, in combination with encorafenib, for BRAF-mutant melanoma expected in mid-2017 -
- See more at: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=2255017#sthash.Y9kiJsug.dpuf

[nferna]

Well, guess we don't have to wait for the 29th after all...

[nferna]

Hey! Wake up, people!

Bini AdComm scheduled for afternoon of March 29. Should be interesting. They are specifically going to discuss the prior checkpoint inhibitor patient data.

https://www.fda.gov/AdvisoryCommittees/Calendar/ucm547160.htm

[Easymoneyman00]

Vid, Thanks again for your AUPH pick it's awesome! I hope I return the favor with ADXS! I've been in ADXS for years over 6 years I'm not selling till we get bought out or $50-$75 a share!Thanks again for this pick!

[grandma_of_jbraika]

vidpok45, thank you very much for your 3 A's recommendations.

[EnigmaTrades]

Tumors have nearly disappeared after a patient treated w/ Array BioPharma drug in clinical trials.

http://denver.cbslocal.com/2016/12/06/social-media-strangers-help-find-treatment-for-girls-cancer/

This company is working on some remarkable drugs and the upside on this stock is huge. There's a reason institutional investment ratio is so high. Huge BO opportunity but even without a buyout, this company has a high probability of doing very well on their own as a company and for shareholder's interests.

Look at their product pipeline: http://www.arraybiopharma.com/product-pipeline/

$ARRY = $$$$

[nferna]

When are they going to schedule the effing AdComm?!

So frustrating!

Thanks for listening

[biotech_researcher]

Android, you are correct. I see 98.8% in institutional ownership with 180 million shares outstanding.

[Android 2-73]

It is when 96% of it is locked up

[biotech_researcher]

Small float? I don't think so. 180 million shares is the float.

[Android 2-73]

small float means MM's need to play games to fill their orders from Tutes.

[DCALongRun]

Just added some more shares during this morning selloff. Interesting that order had to be filled with partial fills. Shares are being shaken from weak hands to strong hands.

[DorseyE]

Check this out
RDHL has1 NDA filling & 2 phase 3 results due by 6/30/2017 + 1 phase 2 due due by 7/31/2017///

[jpinkman]

Rough sailing for ARRY since the $13 mark just a short while ago, no doubt.

ARRY sure has a lot going for it, so wouldn't sweat it just yet, as it is heavily institutionally owned and the BO chances sure seem legit, just not necessarily going to be the crazy BO premium sometimes bantered on these boards. But there is definitely lots more upside based on pipeline and the recent call supported all this...

But need a catalyst here to reverse this trend - at some point may add some shares, but patience may be the preferred strategy here

[biotech_researcher]

ARRY already has a $1.9 billion market cap..

[DCALongRun]

This stock is heavily shorted. It's will have these type of corrections every so often. That's the way biotech stocks are.

Long-term if drugs get approved the stock will go up. Plus its being held by a lot of mutual funds.

[trading_cyclist]

I also bought during the panic selling, but we seem to be going lower. And when I look at the 6 month chart, I suspect the bottom is even lower (which begs the question why I bought during the panic, to which I have no intelligent answer...)

TC

[vidpok45]

I dont feel qualified to answer that question. You know much more about this company than I do at this point. I looked at ARRY's pipeline, their institutional investors, and management and felt that it was likely a buyout would be likely in the relative near future as many have been saying. Denner's departure was a bit disconcerting and probably exacerbated the drop on Thursday, but imo this company has way too much going for it to be overly concerned about his exit. I have nowhere near the full understanding of this complex company to comment about issues I am just beginning to comprehend. I appreciate learning more about it as I read all the articles I can and learn from those like yourself who have been here awhile and appreciate the nuances of this investment better than I do for now.

[vidpok45]

tiv, we should discuss this on the AUPH board. But I see a 10-15X return on AUPH within two years from now.

[DCALongRun]

I picked some shares on 2/16/2017 during the panic selling. There will be many buyers accumulating during pullbacks.

[Lunacy_John Galt]

I got in ARRY before any of the late stage results were released and thought at the time they would try to go to market alone. I'm still inclined to think that way. I know there's a lot of new $ here hoping for quick BO. Other than recent articles written promoting BO, does anyone have a strong argument for BO prior to FDA approval and commercialization?

[afitcher441]

what are your guys thoughts on this as a quick buy in buy out?

not feeling the dd for this but i heard it would be a good one to follow for short term profits

[Hotrodder1]

I understood Vid! Thanks!
I was all in in Ariad. Put only 1/3 of Ariad profits in Auph. Still a consideral sum!

[tiv111]

Vid,
I'm in auph also. Can you elaborate on what you think the timeline might be for the 10x-15x
Thanks

[EnigmaTrades]

Panic selling all day today. A pull back was necessary. Short volume yesterday was highest it has been since January 17. I bet today's short volume was equally large or larger. Options expire tomorrow. Coincidence? I held all day and added a few hundred shares each time I saw large drops. Smart thing to do would have been to sell all or large portion of my position and rebuy at bottom - I just had no idea how low this would go. I'm still strong on my long position. Way more upside potential than some people give this company credit for.

I'm looking forward to next week.

[trading_cyclist]

Smart

[Lunacy_John Galt]

I've been in ARRY & AUPH since low 2s and agree with your sentiment. Big things to come with a little patience.

[Lunacy_John Galt]

Sure seems like a great time to add for anyone that felt like they missed the boat just days ago. Most signs point towards big things to come. Still 90ish inst. ownership regardless of some dude named Denner.

[jpinkman]

This pullback sure seems to have some legs, impressive and powerful - to think the SP was $13 + just a few days ago

tempting to add, but going to be patient and hold off on adding any shares

[vidpok45]

I was congratulating you for buying AUPH, which imo, could be a 10-15 bagger once we get beyond the 48 week data. Today's move in ARRY was a combination of a pullback after a big move up, Denner leaving, and a bad sector day. Nothing at all to do with the fundamentals which remain excellent and should result in a buyout in the 20's within a year or so. Might have a followup decline tomorrow, but will resume its upward path next week I would think.